Savior LLC’s Aurinia Pharmaceuticals AUPH Stock Holding History

Savior LLC’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-801	Closed	-$8.78K	–	131
2023 Q1	$8.78K	Hold	801	–	–	0.01%	93
2022 Q4	$3.46K	Hold	801	–	–	﹤0.01%	129
2022 Q3	$6K	Hold	801	–	–	0.01%	140
2022 Q2	$8K	Hold	801	–	–	0.01%	112
2022 Q1	$10K	Hold	801	–	–	0.01%	105
2021 Q4	$18K	Hold	801	–	–	﹤0.01%	93
2021 Q3	$18K	Hold	801	–	–	0.02%	87
2021 Q2	$10K	Hold	801	–	–	0.01%	402
2021 Q1	$10K	Hold	801	–	–	0.01%	397
2020 Q4	$11K	Hold	801	–	–	0.01%	387
2020 Q3	$12K	Hold	801	–	–	0.01%	333
2020 Q2	$13K	Hold	801	–	–	0.02%	292
2020 Q1	$12K	Hold	801	–	–	0.01%	282
2019 Q4	$16K	Buy	+801	New	+$7.38K	0.02%	334

Other funds holding AUPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Savior LLC's AUPH Position: Q2 2023 in Review

Savior LLC sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2023, closing a stake of 801 shares — an estimated $8.78K sold.

Savior LLC first reported a position in AUPH in Q4 2019 and held it in 14 quarters. The position peaked at $18K in Q4 2021. 200 funds tracked by Wall St. Rank hold AUPH as of Q2 2023.

Savior LLC reported no remaining Aurinia Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Savior LLC sold 801 Aurinia Pharmaceuticals shares in Q2 2023, an estimated $8.78K.
Savior LLC first reported a position in Aurinia Pharmaceuticals in Q4 2019 and held it in 14 quarters.
Savior LLC's Aurinia Pharmaceuticals position peaked at $18K in Q4 2021.
200 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2023.

Based on Savior LLC's 13F filing for Q2 2023, filed 7 Jul 2023.